Mydecine Innovations Group Inc., a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. It also develops MYCO-005, MYCO-006, and MYCO-007 for MDMA and psilocybin analogs. The company has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. Mydecine Innovations Group Inc. was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. The company was incorporated in 2013 and is headquartered in Vancouver, Canada.
Frequently asked questions
What sector does Mydecine Innovations Group Inc (MYCO) operate in?
Mydecine Innovations Group Inc belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Mydecine Innovations Group Inc (MYCO) current stock price?
As of the latest data, Mydecine Innovations Group Inc stock price is CA$2.20, with a previous close of CA$2.20.
What is Mydecine Innovations Group Inc (MYCO) current market capitalization?
Mydecine Innovations Group Inc market cap is approximately 2.72 million.
What is Mydecine Innovations Group Inc (MYCO) Earnings Per Share (EPS)?
The trailing EPS is CA$2.12.
What is Mydecine Innovations Group Inc (MYCO) Price-to-Earnings (P/E) ratio?
Mydecine Innovations Group Inc current P/E ratio is 1.04.
Does Mydecine Innovations Group Inc (MYCO) pay dividends?
No. Mydecine Innovations Group Inc does not pay a dividend.
What is Mydecine Innovations Group Inc (MYCO) beta (volatility) score?
Mydecine Innovations Group Inc has a beta of 1.632, suggesting it is more volatile than the market.
